The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
BullJ.M., TormeyD.C., LiS.H.A randomized comparative trial of Adriamycin versus methotrexate in combination drug therapy. Cancer.1978; 41(5): 1649–57.
2.
AisnerJ., WeinbergV., PerloffM.Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ±MER) for metastatic carcinoma of the breast. J Clin Onc.1987; 5(10): 1523–33.
3.
SmalleyR.V., CarpenterJ., BartolucciA.A comparison of cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-Fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer.1977; 40: 625–32.
4.
NemotoT., HortonJ., SimonR.Comparison of four-combination chemotherapy programs in metastatic breast cancer. Cancer.1982; 49(10): 1988–93.
5.
WoodW.C., BudmanD.R., KorzunA.H.Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med.1994; 330(18): 1253–9.
6.
HeskethP.J., KrisM.G., GrunbergS.M., BeckT., HainsworthJ.D., HarkerG.Proposal for classifying the acute emetogenici-ty of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–9.
7.
American Society of Health-System Pharmacists.ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm.1999; 56(8): 729–64.
8.
National Comprehensive Cancer Network.NCCN antiemesis practice guidelines. Oncology.1997; 11(11A): 57–89.
9.
StillwellT.J., BensonR.C.Cyclophosphamide-induced hem-orrhagic cystitis. A review of 100 patients. Cancer.1988; 61(3): 451–7.
10.
American Society of Clinical Oncology.Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol.1994; 12(11): 2471–2508.
11.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49: 1796–9.
12.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surgery.1985; 75: 397–402.
13.
PattersonW.P., ReamsG.P.Renal and electrolyte abnormalities due to chemotherapy. In: PerryM.C., ed. The Chemotherapy Source Book.2nd ed.Baltimore, MD: Williams and Wilkins; 1996, 727–44.
14.
KingP.D., PerryM.C.Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol Clin North Am.1995; 24(4): 969–90.
